Anika Therapeutics appoints Stephen Griffin as CFO replacing Michael Levitz effective June 3, 2024

Anika Therapeutics, Inc.

Stephen Griffin appointed EVP, CFO and Treasurer of Anika Therapeutics, effective June 3, 2024.
Griffin receives $500K base salary, 60% target bonus, and $2M equity grant split between RSUs and stock options.
Michael Levitz resigned as CFO on May 2; will stay through Dec 31, 2024 for transition, receiving $100K one-time payment.
Levitz's separation includes continued salary through year-end and a general release of claims.

item 5.02 item 9.01

Executive movements

Machine-extracted from this filing. Every card cites the SEC source. See all recent executive movements.

Departed

Michael Levitz

Executive Vice President, Chief Financial Officer and Treasurer

ANIK · Anika Therapeutics, Inc.

Effective: 2024-05-02
Successor: Stephen Griffin
Filed: May 8, 2024, 7:59 PM ET

who tendered his resignation on May 2, 2024

Appointed

Stephen Griffin

Executive Vice President, Chief Financial Officer and Treasurer

ANIK · Anika Therapeutics, Inc.

Effective: 2024-06-03
Filed: May 8, 2024, 7:59 PM ET

announced that Stephen Griffin would be joining the Company as its Executive Vice President, Chief Financial Officer and Treasurer, effective June 3, 2024

Key facts

Extracted from this filing and checked against the source text.

Executive change SEC 8-K Item 5.02 confidence 0.95

Michael Levitz resigned as Executive Vice President, Chief Financial Officer and Treasurer at Anika Therapeutics, Inc..

Action: resigned
Role: Executive Vice President, Chief Financial Officer and Treasurer

Exact text from the filing

who tendered his resignation on May 2, 2024

View on SEC.gov

Executive change SEC 8-K Item 5.02 confidence 0.95

Stephen Griffin was appointed as Executive Vice President, Chief Financial Officer and Treasurer at Anika Therapeutics, Inc..

Action: appointed
Role: Executive Vice President, Chief Financial Officer and Treasurer

Exact text from the filing

announced that Stephen Griffin would be joining the Company as its Executive Vice President, Chief Financial Officer and Treasurer, effective June 3, 2024

View on SEC.gov

Anika Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001171843-24-002673

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.